Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (Weighted Average) (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $58.8 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 2.3% year-over-year to $58.8 million; the TTM value through Mar 2026 reached $58.8 million, up 2.3%, while the annual FY2025 figure was $58.0 million, 2.05% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $58.8 million in Q1 2026 for Agios Pharmaceuticals, up from $58.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $58.8 million in Q1 2026 and bottomed at $54.6 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $56.3 million, with a median of $56.4 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Weighted Average) decreased 21.55% in 2022 and then rose 2.48% in 2024.
  • Agios Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $54.8 million in 2022, then increased by 1.57% to $55.7 million in 2023, then grew by 2.08% to $56.8 million in 2024, then rose by 2.05% to $58.0 million in 2025, then grew by 1.4% to $58.8 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $58.8 million, $58.0 million, and $57.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.